Liquid Biopsy NGS: Fast & Precise Non-Invasive ctDNA Cancer Test
Clinical Overview & Diagnostic Indications
First of all, Non-Invasive ctDNA Cancer Test is the breakthrough non-invasive genomic assay that analyzes circulating tumor DNA (ctDNA) shed into peripheral blood plasma. Essentially, ultra-deep Next-Generation Sequencing (>10,000X depth) detects somatic driver mutations, drug resistance variants, and gene fusions down to 0.1% variant allele frequency without surgical tumor biopsies. Consequently, medical oncologists select FDA-approved targeted therapies and monitor disease recurrence in real time.
Furthermore, book your Non-Invasive ctDNA Cancer Test at Henotic Diagnostics for authoritative precision oncology results. In addition, our accredited genomic laboratory operates 24/7 with specialized Streck cell-free DNA blood collection kits.
📋 Your Liquid Biopsy NGS at a Glance
| 🔍 Detail | 📋 Info |
|---|---|
| 🩺 Technology | Ultra-Deep ctDNA Next-Generation Sequencing (>10,000X) |
| 🩸 Sample Type | 10–20 mL Peripheral Blood in Cell-Free DNA Tubes |
| 💰 Price Range | ₹45,000 – ₹75,000 (All-inclusive diagnostic fee) |
| 📄 Report TAT | 7 to 10 Days (Includes FDA targeted therapy matching) |
| 🕐 Availability | 24/7 Operations (Complimentary Streck tube kit delivery) |
| 👩⚕️ Specialist | Dr. Pratibha Patil — Chief Consultant Radiologist |
| 🍽️ Fasting | No Fasting Required (Normal diet maintained) |
| 💳 Insurance | Reimbursement Documentation Support provided |
| 🏅 Accreditation | NABL Accredited · ISO Certified · CAP Compliant |
Liquid Biopsy NGS Quality Standards & Certifications
Liquid Biopsy NGS: Overview
To begin with, Non-Invasive ctDNA Cancer Test is an advanced, non-invasive genomic diagnostic test that captures fragments of circulating tumor DNA (ctDNA) circulating freely in blood plasma. At the same time, experts at Henotic Diagnostics extract cell-free DNA from blood samples to profile active tumor mutations without requiring painful tissue biopsies.
Furthermore, comfortable reception lounge providing supportive patient registration for non-invasive ctDNA blood testing
What Does Liquid Biopsy NGS Evaluate?
Specifically, Non-Invasive ctDNA Cancer Test evaluates actionable somatic driver mutations (EGFR, KRAS, BRAF, ALK, ROS1, RET), copy number variations, and resistance variants down to 0.1% sensitivity. Consequently, bioinformatic algorithms analyze tumor-derived ctDNA shed from both primary tumors and distant metastases. Furthermore, serial liquid biopsies detect early disease relapse months before radiological detection. As a result, oncologists adjust targeted therapies proactively. In fact, to review liquid biopsy diagnostic guidelines, consult the NCI Liquid Biopsy Cancer Treatment.
Furthermore, Advanced NGS Technology providing comprehensive reports empower oncologists with non-invasive ctDNA targeted therapy insights.
What is Liquid Biopsy NGS?
In general, dying cancer cells release small fragments of mutated genomic DNA (ctDNA) into the bloodstream. Essentially, Non-Invasive ctDNA Cancer Test uses ultra-deep Next-Generation Sequencing (>10,000X coverage) to isolate and sequence these minute ctDNA fragments from blood plasma. Therefore, specialized bioinformatic error-suppression methods distinguish true tumor mutations from background noise. Additionally, to read about clinical liquid biopsy advances, examine the Nature Reviews Clinical Oncology journal.
Additionally, high-throughput NGS sequencers isolate and sequence plasma ctDNA down to 0.1% allele frequency
What Does Liquid Biopsy NGS Check?
Overall, clinical Non-Invasive ctDNA Cancer Test profiling evaluates key oncogenic categories:
Key Somatic Mutations & Resistance Variants Evaluated
In addition, bioinformatic software maps ctDNA mutant allele frequencies and targeted drug response databases
When Is Liquid Biopsy NGS Recommended?
For example, medical oncologists order Non-Invasive ctDNA Cancer Test when surgical tissue biopsy is unsafe, unfeasible, or yields insufficient tissue (NSCLC, colorectal, breast, pancreatic cancer). In particular, testing is recommended upon disease progression during targeted therapy to identify resistance mechanisms without re-biopsy. Moreover, it is used for longitudinal tumor monitoring and post-operative MRD surveillance. In addition, to review NCCN precision oncology guidelines, examine the NCCN Precision Oncology Guidelines.
Moreover, expert molecular tumor boards translate non-invasive ctDNA findings into targeted therapy switches
Clinical Superiority: Non-Invasive ctDNA Blood Profiling vs. Repeat Tissue Biopsy
Ideally, oncologists choose Non-Invasive ctDNA Cancer Test because invasive tissue re-biopsies carry surgical risks, long scheduling delays, and sample bias from a single tumor location. In addition, blood ctDNA captures shed mutations from all metastatic lesions simultaneously. Indeed, to review global cancer diagnostic statistics, consult the WHO Cancer & Diagnostics Fact Sheet.
Liquid Biopsy NGS Cost Guide
| Clinical Liquid Biopsy Service | Approximate Cost (₹) |
|---|---|
| Targeted ctDNA EGFR Resistance Panel (Lung Cancer) | First, targeted ctDNA EGFR pricing is ₹45,000 – ₹52,000 |
| Comprehensive Solid Tumor ctDNA Panel (75+ Genes) | Second, comprehensive 75+ gene ctDNA costs ₹55,000 – ₹65,000 |
| Ultra-Deep Multi-Cancer ctDNA Panel (500+ Genes) | In addition, multi-cancer 500+ gene ctDNA costs ₹68,000 – ₹75,000 |
| Specialized Streck cfDNA Blood Collection Kit | Finally, Streck blood tube kit delivery is complimentary. |
Comparison: Liquid Biopsy NGS vs. Tissue Biopsy NGS
On one hand, Tissue Biopsy NGS remains the diagnostic benchmark when tissue is abundant, whereas Liquid Biopsy NGS offers rapid, non-invasive testing when tissue is unavailable or when monitoring therapy resistance over time. Consequently, both modalities complement modern precision oncology. In fact, review the PubMed Clinical Liquid Biopsy Review.
| Feature | Liquid Biopsy NGS (ctDNA) | Tissue Biopsy NGS (FFPE) |
|---|---|---|
| Invasiveness & Safety | First, 100% non-invasive peripheral blood draw. | However, invasive surgical or core needle biopsy. |
| Turnaround Time | Second, fast report within 7 to 10 days. | In contrast, 14 to 21 days including block retrieval. |
| Tumor Heterogeneity Capture | In addition, captures multi-metastatic ctDNA shedding. | Meanwhile, limited to single biopsy site. |
| Repeat Sampling Frequency | Finally, easily repeated serially during therapy. | Likewise, difficult to repeat serially. |
Frequently Asked Questions
What is Liquid Biopsy NGS? ▼
First, Non-Invasive ctDNA Cancer Test is a simple blood test that extracts and sequences circulating tumor DNA (ctDNA) shed into blood plasma by cancer cells.
How does Liquid Biopsy compare to a traditional tissue biopsy? ▼
In addition, Liquid Biopsy requires only a blood sample without invasive surgery, while overcoming tumor spatial heterogeneity by capturing ctDNA shed from multiple tumor sites.
What sample is required for Liquid Biopsy NGS? ▼
Generally, 10-20 mL of peripheral blood drawn into specialized cell-free DNA preservation tubes (Streck tubes) is required.
Do I need to fast before Liquid Biopsy NGS? ▼
Because ctDNA profiling evaluates cell-free tumor DNA, fasting is unnecessary.
Can Liquid Biopsy NGS detect drug resistance mutations? ▼
Furthermore, Liquid Biopsy NGS excels at tracking emergent resistance mutations like EGFR T790M or C797S during ongoing targeted cancer therapy.
What is the cost of Liquid Biopsy NGS? ▼
Overall, high-precision Liquid Biopsy NGS ranges from ₹45,000 to ₹75,000 depending on panel size and gene target breadth.
Quick Appointment Booking
Schedule your Liquid Biopsy NGS with accredited genomic experts.
Call: 088793 27184 WhatsApp BookingTest Summary
Reporting Clinical Genomic Specialist
Dr. Pratibha Patil
Chief Consultant Radiologist & Clinical Diagnostics Specialist
MBBS, MD (Radiodiagnosis) · 15+ Years Clinical Experience
Furthermore, your Liquid Biopsy NGS data is evaluated by accredited molecular geneticists and bioinformaticians. Consequently, comprehensive reports empower oncologists with non-invasive ctDNA targeted therapy insights.
Our Accreditations & Quality Standards
Certified excellence ensuring ctDNA sequencing depth, bioinformatic variant calling accuracy, and patient privacy.
What Our Patients Say
Real feedback from patients who completed Liquid Biopsy NGS testing with us.
“Liquid Biopsy NGS detected the EGFR T790M resistance mutation in my blood when lung tissue biopsy was too risky. Furthermore, changing my medication cleared the disease!”
– Vikram S.
Verified Patient Review“Complimentary Streck blood tube kit delivery and extremely fast 7-day turnaround. In addition, the oncologist praised the clinical report depth.”
– Rekha M.
Verified Patient Review“State-of-the-art NABL accredited ctDNA platform. Henotic Diagnostics is our trusted referral laboratory for non-invasive liquid biopsy monitoring.”
– Dr. Preeti G.
Verified Medical Oncologist ReviewRelevant Diagnostic Oncology & Genomic Services
Corporate Booking Office & Location
If you require Liquid Biopsy NGS for non-invasive ctDNA mutation profiling or resistance monitoring, do not delay. Call to schedule your sample collection.
Henotic Diagnostics
Second floor, Millennium Empire, Business Park, Plot No 47, D Mart Rd, Sector 15, Kharghar, Navi Mumbai, Panvel, Maharashtra 410210
Phone: 088793 27184 | Hours: Open 24 Hours